智通财经APP讯，科济药业-B(02171)发布公告，赛恺泽®(泽沃基奥仑赛注射液，产品编号： CT053，一种靶向BCMA的自体CAR-T细胞产品)的长期随访更新结果已在第 22届国际骨髓瘤学会年会上进行壁报展示。
赛恺泽® I期临床试验更新结果已于多伦多时间2025年9月17日早上，在第22 届IMS年会上进行壁报展示，标题为“复发╱难治性多发性骨髓瘤患者接受 zevor-cel治疗的长期随访”(“Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma”)。
赛恺泽®是一种用于治疗多发性骨髓瘤(MM)的全人抗自体BCMA CAR-T细胞产品。国家药品监督管理局于2024年2月23日批准赛恺泽®新药上市申请，用于治疗复发或难治性多发性骨髓瘤成人患者，既往经过至少3线治疗后进展(至少使用过一种蛋白酶体抑制剂及免疫调节剂)。泽沃基奥仑赛注射液于2019年获得美国 FDA的再生医学先进疗法(RMAT)及孤儿药称号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.